InhaleRx Limited (AU:IRX) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
InhaleRx Limited has secured a $38.5 million funding agreement with Clendon Biotech Capital to advance its clinical development projects, IRX-211 and IRX-616a, through Phase 2 trials. This strategic partnership enables the company to focus on creating breakthrough inhaled therapies for pain management and mental health, potentially reaching Phase 3 within the next few years. InhaleRx aims to solidify its position as a leader in inhaled therapeutics, addressing unmet medical needs and enhancing patient care.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.